Physician profile
Ryan A Unger
NPI 1891926440
$11,697.20
in general payments reported to CMS, 2019-2025
68 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,667 · 2020: $2,427 · 2021: $2,281 · 2022: $1,803 · 2023: $372 · 2024: $1,513 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,494.50 | 2019-2025 | Grafix Pl, Stravix Pl, Grafix |
| Astrazeneca Pharmaceuticals LP | $913.01 | 2019-2022 | |
| Novo Nordisk INC | $840.39 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $721.70 | 2019-2023 | Dalvance |
| Allergan, INC. | $677.76 | 2019-2020 | |
| Lilly USA, LLC | $576.25 | 2019-2022 | |
| Glaxosmithkline, LLC. | $553.76 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.79 | 2019-2022 | |
| Mannkind Corporation | $323.63 | 2019-2022 | |
| Musculoskeletal Transplant Foundation INC. | $288.47 | 2020 | |
| Medtronic, INC. | $286.82 | 2021-2025 | Endurant Iis, Venaseal |
| Takeda Pharmaceuticals U.S.A., INC. | $262.32 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $258.04 | 2020-2024 | Nuzyra |
| Abbott Laboratories | $255.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $248.71 | 2019-2021 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Unger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.